Clinical trial Recruiting at 11 sites Phase 4 Interventional Ages 18 and up

Comparing two antibiotic treatments for joint infections caused by Staphylococcus

Official title: Rifampicin Combination Therapy Versus Targeted Antimicrobial Monotherapy in the Oral Antimicrobial Treatment Phase of Staphylococcal Prosthetic Joint Infection

Run by Leiden University Medical Center · NCT06172010 · Data updated 2026-11-12

This study tests whether a combination of two antibiotics can work better than just one to treat joint infections caused by Staphylococcus in adults with hip or knee infections.

More Prosthetic Joint Infection trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment316 (estimated)
SponsorLeiden University Medical Center
Academic / other
Drugs / interventionschemotherapy
Locations13 sites (Leiden, Zuid Hollans and 12 other locations)
StatusRecruiting
StartedApril 1, 2023
Main results expectedMarch 2027
Study endsMarch 2028
Registry record updatedDecember 15, 2023
Trial IDNCT06172010 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 with confirmed staphylococcal prosthetic hip or knee joint infections treated by the DAIR strategy.

Probably not a fit

Patients with contraindications to rifampicin, levofloxacin, or clindamycin, or those requiring long-term intravenous antibiotic treatment may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter clinical trial in the Netherlands aims to compare the effectiveness of rifampicin and levofloxacin combination therapy against clindamycin monotherapy in treating staphylococcal prosthetic joint infections. Patients aged 18 and older diagnosed with hip or knee infections will be randomized to receive either treatment during the oral antibiotic phase. The study will follow participants for 15 months to assess treatment success based on predefined clinical endpoints. The trial employs a pragmatic, randomized controlled design to evaluate the non-inferiority of the combination therapy.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for patients suffering from staphylococcal prosthetic joint infections.

How similar studies have gone: Previous studies have shown promise in using combination antibiotic therapies for similar infections, but this specific approach is being evaluated for the first time.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* \>18 years of age
* Confirmed staphylococcal prosthetic hip or knee joint infection according to the current EBJIS 2021 definition of PJI
* The causative agents are (or include) S. aureus or and/or Coagulase-negative staphylococci (CNS)
* Treatment is according to the DAIR-procedure

Exclusion Criteria:

(i) a contra-indication for rifampicin (e.g. a resistant strain or proven allergic reaction or difficult drug-drug-interactions) (ii) complicated S. aureus bacteremia or concurrent endocarditis requiring long-term iv antibiotic treatment \> 2 weeks (iii) An infection for which there are no suitable antibiotic choices to permit Randomization between the two arms of the trial (for instance, where organisms are only sensitive to intravenous antibiotics) (iv) treatment failure before the start of oral therapy, (v) an unsatisfactory response to initial treatment leading to continuation of intravenous therapy beyond day 21, (vi) patients with an expected life expectancy \<12 months, (vii) patients with a tumor prosthesis (viii) patients receiving chemotherapy for active malignancy in the next 12 months (ix) patients who are scheduled in advance for chronic suppressive antibiotic therapy for \>12 months, (x) The patient is unlikely to comply with trial requirements following Randomization in the opinion of the investigator (xi) Pregnancy (xii) Patients who are not able to read or communicate in Dutch or English will be excluded from participating in this study

Where it's running

  • Lumc
    Leiden, Zuid Hollans, Netherlands
    Recruiting
  • Amsterdam UMC
    Amsterdam, Netherlands
    Recruiting
  • Olvg
    Amsterdam, Netherlands
    Recruiting
  • Umcg
    Groningen, Netherlands
    Recruiting
  • Spaarne gasthuis
    Hoofddorp, Netherlands
    Recruiting
  • Medisch Centrum Leeuwarden
    Leeuwarden, Netherlands
    Recruiting
Show 7 more locations
  • Alrijne Ziekenhuis
    Leiderdorp, Netherlands
    Recruiting
  • Radboud UMC
    Nijmegen, Netherlands
    Recruiting
  • Sint maartenskliniek
    Nijmegen, Netherlands
    Recruiting
  • Elisabeth Tweesteden Ziekenhus
    Tilburg, Netherlands
    Recruiting
  • Stichting Isala Klinieken
    Zwolle, Netherlands
    Recruiting
  • Martini ziekenhuis
    Groningen, Netherlands
    Not yet recruiting
  • Erasmus MC
    Rotterdam, Netherlands
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.